Literature DB >> 22593455

Survival of a patient with anaplastic thyroid cancer following intensity-modulated radiotherapy and sunitinib--a case report.

Jonathan D Schoenfeld1, Oreofe O Odejide, Lori J Wirth, Annie W Chan.   

Abstract

BACKGROUND: Anaplastic thyroid cancer has a very poor prognosis, especially in patients who have gross residual disease following resection. CASE REPORT: We present the case of a patient with anaplastic thyroid cancer and a significant gross residual disease treated with intensity-modulated radiotherapy with concurrent chemotherapy and sunitinib who had a complete response and remains without evidence of disease more than 18 months after diagnosis.
CONCLUSION: Chemoradiotherapy has an important role in the adjuvant treatment of anaplastic thyroid cancer in selected patients and should be considered when gross residual disease is present following resection. The combined use of radiotherapy and targeted biological agents such as sunitinib may warrant further investigation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22593455

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Anaplastic thyroid cancer: outcome and the mutation/expression profiles of potential targets.

Authors:  Hao Wu; Yue Sun; Huihui Ye; Shi Yang; Stephanie L Lee; Antonio de las Morenas
Journal:  Pathol Oncol Res       Date:  2015-01-15       Impact factor: 3.201

2.  Cell Cycle M-Phase Genes Are Highly Upregulated in Anaplastic Thyroid Carcinoma.

Authors:  Paul Weinberger; Sithara Raju Ponny; Hongyan Xu; Shan Bai; Robert Smallridge; John Copland; Ashok Sharma
Journal:  Thyroid       Date:  2016-12-15       Impact factor: 6.568

3.  Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).

Authors:  Junaid Abdulghani; Prashanth Gokare; Jean-Nicolas Gallant; David Dicker; Tiffany Whitcomb; Timothy Cooper; Jiangang Liao; Jonathan Derr; Jing Liu; David Goldenberg; Niklas K Finnberg; Wafik S El-Deiry
Journal:  Clin Cancer Res       Date:  2016-06-15       Impact factor: 12.531

4.  Enlarging neck masses in the elderly - Histological and surgical considerations.

Authors:  M D O'Sullivan; K S McAnena; C Egan; P S Waters; P J McCann; M J Kerin
Journal:  Int J Surg Case Rep       Date:  2013-01-17

5.  Synergistic efficacy of irinotecan and sunitinib combination in preclinical models of anaplastic thyroid cancer.

Authors:  Teresa Di Desidero; Alessandro Antonelli; Paola Orlandi; Silvia Martina Ferrari; Anna Fioravanti; Greta Alì; Gabriella Fontanini; Fulvio Basolo; Giulio Francia; Guido Bocci
Journal:  Cancer Lett       Date:  2017-09-28       Impact factor: 8.679

6.  Anaplastic thyroid carcinoma and foscarnet use in a multitarget treatment documented by 18F-FDG PET/CT: A case report.

Authors:  Elisa Giannetta; Andrea M Isidori; Cosimo Durante; Cira Di Gioia; Flavia Longo; Vincenzo Tombolini; Nadia Bulzonetti; Chiara Graziadio; Riccardo Pofi; Daniele Gianfrilli; Antonella Verrienti; Raffaella Carletti; Sebastiano Filetti; Andrea Lenzi; Alberto Baroli
Journal:  Medicine (Baltimore)       Date:  2017-02       Impact factor: 1.889

7.  Cytokeratin-8 in Anaplastic Thyroid Carcinoma: More Than a Simple Structural Cytoskeletal Protein.

Authors:  Dehuang Guo; Qinqin Xu; Sarabjot Pabla; John Koomen; Paul Biddinger; Ashok Sharma; Simarjot Pabla; Rafal Pacholczyk; Chien-Chung Chang; Kevin Friedrich; Kamran Mohammed; Robert C Smallridge; John A Copland; Jin-Xiong She; Paul M Weinberger
Journal:  Int J Mol Sci       Date:  2018-02-14       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.